Which fillers (diluents) are commonly used in ivermectin 3 mg and 6 mg tablets?

1. What the manufacturer label actually says — the short list of excipients

The authoritative, clinician-facing product information for ivermectin tablets (Stromectol/generic tablet labels) lists five inactive ingredients: microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, pregelatinized starch, and magnesium stearate ^[1]. This is the clearest, primary-candidate answer because the package insert is the industry standard for what is physically in the commercial tablet ^[1].

2. Why those ingredients are used — functional roles in tablets

The named excipients serve familiar pharmaceutical roles: microcrystalline cellulose and pregelatinized starch act as fillers/binders to give tablet mass and cohesion; croscarmellose sodium is a disintegrant that helps the tablet break apart after swallowing; colloidal silicon dioxide controls flow and moisture; and magnesium stearate is a common lubricant to aid tablet compression and ejection from manufacturing equipment ^[1]. The package insert lists the ingredients but does not provide the quantitative proportions or manufacturing process details ^[1].

3. Strengths sold and what labels confirm about strengths

Most clinical and regulatory references describe ivermectin tablets in a 3 mg strength and note that tablets may be given in combinations to reach higher doses (for example, clinicians may prescribe multiple 3 mg tablets to reach a 12 mg dose for some uses) ^{[3] [4]}. The product insert specifically notes the availability of 3 mg and 6 mg tablets and gives clinical pharmacology and dosing tables consistent with the 3 mg tablet unit ^{[1] [2]}.

4. What the broader literature and online vendors say — agreement and gaps

Drug databases and prescribing guides (Mayo Clinic, Drugs.com, Dailymed) focus on dosing, indications and safety; they cite the tablet strength and dosing but generally rely on the same label for excipient information and do not add alternative filler lists ^{[3] [5] [2]}. Commercial or vendor sites sometimes claim “no unnecessary fillers” or “pharmaceutical grade” without offering independent verification; those claims are promotional and not substantiated in the regulatory label documents provided here ^[6]. Available sources do not mention any other filler or binder formulations beyond the package insert list ^[1].

5. Variability across manufacturers and generics — what to expect

Generic manufacturers may use equivalent excipients to achieve the same tablet performance, but the exact inactive ingredient mix and their amounts can vary by manufacturer. The FDA-approved label for a marketed tablet specifies the excipients for that approved product; generics must demonstrate bioequivalence but may list slightly different excipients in their labels if they use different formulations — however, the set of excipients named in the referenced package insert is what is documented for the approved product cited ^[1]. Specific generic product labels and their excipients are not enumerated in the sources provided here (not found in current reporting).

6. Practical implications for patients and clinicians

If a patient has allergies, intolerances, or sensitivities to particular excipients (for example, to certain starches or lubricants), clinicians and pharmacists should check the specific product label or the pharmacy’s product information to confirm which inactive ingredients are present; the product insert supplies the list for the referenced marketed tablet ^[1]. For dosing questions and clinical indications, major clinical resources and regulatory materials reiterate that dosing is weight-based and that ivermectin tablets are primarily available as 3 mg units ^{[3] [2]}.

Limitations: this analysis relies on the cited package insert and standard drug references; it does not include proprietary formulation details from all generic manufacturers, and the sources do not provide excipient quantities or manufacturing specifics ^{[1] [2]}.